These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8738403)

  • 1. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.
    Walther MM; Figg WD; Linehan WM
    World J Urol; 1996; 14 Suppl 1():S8-11. PubMed ID: 8738403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
    Uchio EM; Linehan WM; Figg WD; Walther MM
    J Urol; 2003 Jan; 169(1):357-60. PubMed ID: 12478189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
    Ord JJ; Streeter E; Jones A; Le Monnier K; Cranston D; Crew J; Joel SP; Rogers MA; Banks RE; Roberts IS; Harris AL
    Br J Cancer; 2005 Jun; 92(12):2140-7. PubMed ID: 15928663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical suramin in the prevention of transitional cell carcinoma.
    Graham SD; Napalkov P; Oladele A; Keane TE; Petros JA; Clarke HS; Kassabian VS; Dillehay DL
    Urology; 1995 Jan; 45(1):59-63. PubMed ID: 7817482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS; Jordan AM; Murphy WM
    Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy.
    Huncharek M; Kupelnick B
    Am J Clin Oncol; 2004 Oct; 27(5):522-8. PubMed ID: 15596924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
    Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
    Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical therapy for superficial bladder cancer.
    Baselli EC; Greenberg RE
    Oncology (Williston Park); 2000 May; 14(5):719-29; discussion 729-31, 734, 737. PubMed ID: 10853462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
    Hardeman SW; Perry A; Soloway MS
    J Urol; 1988 Aug; 140(2):289-92. PubMed ID: 3135420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
    Huncharek M; Kupelnick B
    Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.
    Puri R; Palit V; Loadman PM; Flannigan M; Shah T; Choudry GA; Basu S; Double JA; Lenaz G; Chawla S; Beer M; Van Kalken C; de Boer R; Beijnen JH; Twelves CJ; Phillips RM
    J Urol; 2006 Oct; 176(4 Pt 1):1344-8. PubMed ID: 16952628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines.
    Walther MM; Trahan EE; Cooper M; Venzon D; Linehan WM
    J Urol; 1994 Nov; 152(5 Pt 1):1599-602. PubMed ID: 7933214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is intravesical chemotherapy for superficial bladder cancer still justified?
    Okeke AA; Probert JL; Gillatt DA; Schwaibold H
    BJU Int; 2005 Oct; 96(6):763-7. PubMed ID: 16153195
    [No Abstract]   [Full Text] [Related]  

  • 17. When should we stop intravesical treatment in patients with superficial bladder cancer?
    von Heyden B; Jakse G
    Recent Results Cancer Res; 1993; 126():127-33. PubMed ID: 8456183
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravesical RTNF therapy of superficial bladder cancer. A phase I study of recombinant tumor necrosis factor administered intravesically to patients with superficial bladder cancer.
    Grampsas SA; Kahn K; Crawford ED
    Online J Curr Clin Trials; 1994 Mar; Doc No 117():[4845 words; 36 paragraphs]. PubMed ID: 8136939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials.
    Huncharek M; Geschwind JF; Witherspoon B; McGarry R; Adcock D
    J Clin Epidemiol; 2000 Jul; 53(7):676-80. PubMed ID: 10941943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Endovesical chemotherapy for superficial bladder tumors].
    Chopin D; Gattegno B
    Prog Urol; 2001 Nov; 11(5):1047-64. PubMed ID: 11769074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.